Zonisamide is a voltage-dependent sodium channel and T-type calcium channel blocker, used as an antiepileptic drug.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||42 mg/mL in DMSO|
Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
Murata M, et al. Mov Disord. 2015 Sep;30(10):1343-50. PMID: 26094993.
|Related Sodium Channel Products|
GNE-131 is a potent and selective inhibitor of human sodium channel NaV1.7, with an IC50 of 3 nM.
PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC50 of 380 nM.
Eleclazine HCl is a novel late Na+ current inhibitor, with IC50 value of 0.7 uM.
Levobupivacaine is a reversible neuronal sodium channel inhibitor.
PF-05089771 is a selective Nav1.7 channel blocker that interacts with the voltage-sensor domain (VSD) of domain IV.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.